Evidence map›Paper›PMID 35421792›Full record

ArticleComputers in biology and medicine2022

MutCov: A pipeline for evaluating the effect of mutations in spike protein on infectivity and antigenicity of SARS-CoV-2.

Wenyang Zhou, Chang Xu, Meng Luo, Pingping Wang, Zhaochun Xu, Guangfu Xue, Xiyun Jin, Yan Huang, Yiqun Li, Huan Nie and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Computers in biology and medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Wenyang ZhouSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, 150000, China.
Chang XuSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, 150000, China.
Meng LuoSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, 150000, China.
Pingping WangSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, 150000, China.
Zhaochun XuSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, 150000, China.
Guangfu XueSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, 150000, China.
Xiyun JinSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, 150000, China.
Yan HuangSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, 150000, China.
Yiqun LiSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, 150000, China.
Huan NieSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, 150000, China.
Qinghua JiangSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, 150000, China. Electronic address: qhjiang@hit.edu.cn.
Anastasia A AnashkinaEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia. Electronic address: anastasia.a.anashkina@mail.ru.
Harbin Institute of Technology · CNEngelhardt Institute of Molecular Biology · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing an outbreak of coronavirus disease 2019 (COVID-19), is a major threat to public health worldwide. Previous studies have shown that the spike protein of SARS-CoV-2 determines viral infectivity and major antigenicity. However, the spike protein has been undergoing various mutations, which bring a great challenge to the prevention and treatment of COVID-19. Here we present the MutCov, a pipeline for evaluating the effect of mutations in spike protein on infectivity and antigenicity of SARS-CoV-2 by calculating the binding free energy between spike protein and angiotensin-converting enzyme 2 (ACE2) or neutralizing monoclonal antibody (mAb). The predicted infectivity and antigenicity were highly consistent with biologically experimental results, and demonstrated that the MutCov achieved good prediction performance. In conclusion, the MutCov is of high importance for systematically evaluating the effect of novel mutations and improving the prevention and treatment of COVID-19. The source code and installation instruction of MutCov are freely available at http://jianglab.org.cn/MutCov.

Indexed as

COVID-19SARS-CoV-2Antibodies, NeutralizingHumansMutationProtein BindingSpike Glycoprotein, CoronavirusAntibodies, NeutralizingSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2AntigenicityInfectivityMutationSARS-CoV-2Spike protein

Identifiers

PMID35421792
PMCPMC8993498
OpenAlexW4223994828

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.